An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan

Recruiting

• Conditions: Ulcerative Colitis

• Registration Number: NCT05791526
• Lead Sponsor: AbbVie

Brief Summary

Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. This study will assess how safe and effective Rinvoq is in treating adult participants with moderate to severe ulcerative colitis (UC). Adverse events and change in disease activity will be assessed.

Rinvoq is a drug approved for the treatment of ulcerative colitis (UC). All study participants will receive Rinvoq as prescribed by their study doctor in accordance with approved local label. Approximately 300 adult participants will be enrolled in Japan.

Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 60 weeks.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-19
• Study First Submitted: 2023-03-17
• Study First Submitted QC: 2023-03-17
• Study First Posted: 2023-03-30
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-15
• Last Update Posted: 2025-07-17
• Primary Completion: 2025-11-30
• Study Completion: 2025-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Participants diagnosed with moderately to severely active Ulcerative colitis (UC).
• Participants who are within 14 days from the commencement of Rinvoq treatment for UC.
• Participants who are administered the first dose of Rinvoq for UC after approval for UC in Japan.

Exclusion Criteria

• Participants currently participating in registrational clinical trial.
• Participants for whom Rinvoq is contraindicated.
• Participants that have been previously exposed to Rinvoq.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence Percentage of Serious Infection Reported as Adverse Drug Reaction (ADR)	Up to 60 weeks	An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.

Trial Locations

Locations (108)

Anjou Kousei Hospital /ID# 256207; 🇯🇵 Anjo-shi, Aichi, Japan

Ichinomiyanishi Hospital /ID# 259498; 🇯🇵 Ichinomiya-shi, Aichi, Japan

Aikawa Minnano-shinryojo /ID# 258447; 🇯🇵 Nagoya-shi, Aichi, Japan

Shimozato Clinic /ID# 261901; 🇯🇵 Nagoya-shi, Aichi, Japan

Miwa Internist and Gastroenterology Clinic Aoi /ID# 267049; 🇯🇵 Nagoya-shi, Aichi, Japan

Yamada Coloproctology Clinic /ID# 259508; 🇯🇵 Niwa-gun, Aichi, Japan

Ieda Hospital /ID# 257012; 🇯🇵 Toyota-shi, Aichi, Japan

Asahi General Hospital /ID# 258446; 🇯🇵 Asahi-shi, Chiba, Japan

Chiba Clinic /ID# 257015; 🇯🇵 Chiba-shi, Chiba, Japan

Nippon Medical Chiba Hokusoh Hospital /ID# 259505; 🇯🇵 Inzai-shi, Chiba, Japan

Scroll for more (98 remaining)